They plan to get a partner for conducting Ph3
trial on PSMA.
In taxane-experienced mCRPC treated with PSMA ADC at doses of 2.3 mg/kg, reductions of PSA ≥30% are seen in ~38% and reductions of ≥50% are seen in ~16% of patients • CTC conversion from unfavorable to fa vorable occurs in ~45% of patients • PSMA Expression correlates well to PSA and CTC (p=0.019) response to PSMA ADC • Low NE markers correlate well to PSA (p=0.012) response with CTC reduction of 50% in 78% of patients • 2.3 mg/kg is generally well tolerated and appears to be better tolerated than 2.5 mg/kg • A taxane-naïve cohort is ongoing
"We are encouraged by the tolerability and clear activity of PSMA ADC in this heavily pre-treated population," said Hagop Youssoufian, M.D., Executive Vice President, Research and Development. "For example, reductions in CTC's of more than 50% were seen in over 70% of patients treated."
Dr Youssoufian also said, "we look forward to the upcoming data in the less clinically advanced chemo naive setting, where our ADC technology may provide an even greater clinical benefit to men with prostate cancer."
"I've been encouraged by the response seen to date in our patients," said Daniel Petrylak, M.D., Professor of Medical Oncology at Yale Cancer Center, Clinical Research Program Leader for the Prostate and Urologic Cancers Program at Smilow Cancer Hospital at Yale-New Haven, and lead investigator on the trial. "I believe that the 2.3 mg/kg dose has been well tolerated," added Dr. Petrylak.
"We have long held the belief that PSMA expression would correlate with response, and were pleased to see that correlation in this trial. I was also pleased that another biomarker that measures low neuroendocrine disease also correlates and offers the ability to identify responders in this trial through the use of a simple blood test," said Mark R. Baker, CEO of Progenics.
Happened with Adcetris, Mylotarg, Kadcycla which are all approved and are same class of ADC.
Immunospressed cancer patients are prone to infection.
. I am hearing that they may feel that their drug still works fine with lower dosage however they may need to raise money to fund a longer study. Check Twitter for "PGNX"
By the way, severe sepsis is responsible for the death of 10% of all cancer deaths.
We will wait and see.
This sort of conspiracy talk is nonsense.
Oversold bounce coming & Stifel maintains its Hold rating on Progenics. Other product in the pipeline and Relistor drug is already in the market being sold.
Toxicity levels were too high across the group...